Nov. 8, 2021 – Whether consumers and healthcare professionals (HCPs) are influenced by “targeted mechanism of action (MoA)” presentations in promotional materials for drugs is the subject of a proposed study by FDA’s Office of Prescription Drug Promotion (OPDP) research division. Public comments on the information collection activities associated with this research proposal are due […]
Read more
Dec. 22, 2017 — The FDA recently announced that it was planning to study whether consumers and healthcare professionals have the ability to “spot and report” deceptive prescription drug promotion practices (https://www.gpo.gov/fdsys/pkg/FR-2017-12-12/pdf/2017-26704.pdf). The FDA’s Office of Prescription Drug Promotion (OPDP), which issued the lowest number of enforcement letters ever in 2017, appears to be looking […]
Read moreAug. 12, 2013 — An increasing focus on the healthcare consumer’s needs and preferences may play a role in future industry product development priorities. According to a recent health survey commissioned the Pharmaceutical Research and Manufacturers of America (PhRMA), 86 percent of Americans believe that developing cures for more forms of cancer should be one […]
Read moreNEW YORK – (BUSINESS WIRE) – According to Prevention Magazine’s 13th annual national survey Consumer Reaction to DTC Advertising of Prescription Drugs, consumers are paying attention to the FDA regulated “fair balance” mandate between risk and benefit information on all DTC ads; the majority believe pharmaceutical advertising in magazines and television is presented “both fair […]
Read more